PCAR — PACCAR Inc

The market is genuinely split. Bulls point to the Q2 2026 beat (EPS $1.43 vs. ~$1.33-1.36 expected, revenue $7.55B), aftermarket parts pacing near record levels, JPMorgan's $164 Overweight and Evercore's $162 Outperform, and the EPA 2027 pre-buy as a visible order catalyst. Bears point to the tape: as of 2026-09-13 the stock was down 6.36% over the prior month and 1.58% over the week, RSI(14) sat at 39.37, and price was 2.79% below the 20-day and 4.09% below the 50-day SMA. The CEO's disposal of 50,975 shares (~$6.8M) on 2026-07-31 didn't help optics. The institutional consensus is a Hold with 30 of 45 ratings at Hold or worse, and price targets unusually wide ($125 Morgan Stanley to $164 JPMorgan) — the definition of a 'show-me' stock.

This is a clear cyclical deceleration that appears to have troughed, not a structural decline. Revenue peaked at $9.08B in Q4 2023 and slid every quarter for eight straight periods — $8.77B (Q2 2024), $8.24B, $7.91B, $7.44B, $7.51B, $6.67B (Q3 2025), $6.82B, to a low of $6.23B in Q1 2026 — before snapping back +21% QoQ to $7.55B in Q2 2026. Diluted EPS tells the same story: from $2.70 (Q4 2023) to $2.27, $2.13, $1.85, $1.66, $0.96 (Q1 2025, distorted by a charge — net income of $505M against $885M of operating income), $1.37, $1.12, $1.06, $1.15, and now $1.43. Operating margin compressed from ~15.3% in Q2 2024 to a trough of 8.8% in Q4 2025 (Q3 2025: 9.5%), then expanded to 9.0% in Q1 2026 and 11.65% in Q2 2026 — roughly 285bp of recovery in two quarters. Gross margin shows the same inflection: 17.0% (Q2 2025) → 13.83% (Q4 2025) → 13.12% (Q1 2026) → 16.07% (Q2 2026). The one structural support through the whole down-cycle is R&D holding steady at $106-115M per quarter and aftermarket parts near records — that's what separates a PACCAR cycle from a pure truck-build cycle. The key caveat: a 21% sequential bounce off one quarter is an inflection signal, not yet a proven trend.

Expensive on trailing numbers, full-but-not-absurd on forward numbers. As of 2026-09-13 the stock's TTM P/E was 25.78x (EPS $4.752) against a 5-year average P/E of just 15.27x, and P/S was 2.37x vs. a 5-year average of 1.52x — the 'Rich vs. its own history' label is directionally correct. But the 5-year average is a peak-earnings artifact: it was struck while 2023-24 EPS sat near $8-9, so a low trailing P/E then was mechanical. The more honest forward math: $122.73 / $5.948 next-FY consensus EPS = 20.6x, which is still a ~35% premium to the historical 15.27x average. P/B of 3.18x against ROE of 12.3% and ROIC of 6.2% is not a cheap combination. Verdict: you are paying a premium multiple for a recovery that has only one quarter of evidence behind it.

The setup is 'recovery partly paid for.' At $122.73 the stock sits below both the $136 consensus target and the $139.24 52-week high, so the market has not fully capitalized the up-cycle — but a 25.78x TTM P/E on trough-ish EPS and 20.6x forward means it has already capitalized a good chunk of the rebound in the denominator. That leaves an asymmetric bar: simply hitting the $5.948 FY2027 consensus likely keeps the multiple above its own history and produces limited upside; the stock needs EPS to clear $6.50-7.00 or management to signal 2027 build rates above plan for real re-rating. On the downside, the biggest trap is reading the EPA 2027 pre-buy as pure growth — if it pulls 2028 demand into 2027, the 'recovery' is a one-year air pocket and the forward E in that 20.6x multiple evaporates. Watch Q3 2026 guidance on 2027 order intake on 2026-10-20 as the decisive datapoint.

Short-term weak within a longer-term intact trend. As of 2026-09-13, RSI(14) was 39.37 — weak but not yet oversold — price was 2.79% below the SMA20 and 4.09% below the SMA50, while still 2.01% above the SMA200. Returns: -1.58% over 1 week, -6.36% over 1 month, but +3.55% over 3 months and +6.41% over 6 months. That is a pullback inside an uptrend, with the 200-day acting as the line in the sand. Timing implication: RSI near 39 is not a compelling contrarian entry on its own — there's room to drift toward 30. The higher-quality entry is either a test of the 200-day (roughly the $120 area given the current SMA) with RSI under 35, or a confirmed reclaim of the 50-day on rising volume after the Q3 print. Chasing here means buying mid-pullback with no oversold cushion.

• EPA 2027 emissions standards: fleets are expected to pull forward heavy-duty purchases ahead of the mandate, a real near-term order tailwind for late 2026/2027 — but it risks borrowing demand from 2028 and creating a payback air pocket.
• North American freight cycle: improving spot rates are reviving carrier capital spending, with H2 2026 NA heavy-duty retail sales projected near 145,000 units — the single biggest swing factor for PACCAR's truck segment (~60% of the business).
• Tariffs and input-cost inflation: management has flagged shifting tariff policy and localized supply risk as live pressures on truck gross margin, which at 14.9% TTM is already well below the 17%+ levels of 2024.
• Interest rates and credit: PACCAR Financial Services finances dealer and customer purchases — higher rates raise funding costs, dampen equipment demand, and pressure used-truck residual values, which flow back through segment profit.
• Geographic divergence: Europe (~25% of revenue) is stabilizing while South America stays soft, so FX translation and regional build-rate decisions add noise to an otherwise improving North American picture.
• Industrial sector rotation: with a 0.97 beta and a 2.11% dividend yield, PCAR trades as a defensible industrial — it will lag if capital rotates into higher-beta cyclicals and outperform if the market de-risks.

• Q3 2026 earnings expected around 2026-10-20 — the critical read on Q4 build rates, 2027 order intake, tariff cost pass-through, and whether the Q2 margin inflection is real.
• EPA 2027 pre-buy: accelerating North American order intake through late 2026 and 2027 as fleets buy ahead of the mandate.
• Aftermarket parts strength: currently pacing near record levels, and it is the highest-margin, most recurring piece of the portfolio — continued strength would lift blended margin even if truck volumes disappoint.
• Capital returns: the $0.35 quarterly dividend (ex-date 2026-08-12) is covered with room to spare; PACCAR has a history of special dividends and buybacks at cycle turns, and continued share retirement flatters EPS math.
• Freight rate recovery translating into fleet capex: if spot rates keep improving, the NA replacement cycle could extend beyond the EPA-driven pre-buy.

• Cyclicality, plain and simple: EPS has already fallen from $2.70 a quarter (Q4 2023) to $1.43, and revenue from $9.08B to a $6.23B trough. One quarter of sequential improvement is not proof the down-cycle is over.
• Valuation risk: a 20.6x forward P/E and 3.18x book against a 15.27x five-year average P/E and 12.3% ROE leaves essentially no margin of safety if the recovery stalls — multiple compression would compound an earnings miss.
• Margin pressure from tariffs and supply-chain cost inflation: TTM gross margin of 14.9% and operating margin of 9.8% are well below 2024 levels, and cost pass-through in a competitive truck market is not guaranteed.
• EPA 2027 pull-forward payback: if the pre-buy merely shifts 2028 volume into 2027, the market may be capitalizing a one-year spike as a durable recovery.
• Financial Services credit and residual-value exposure: a soft freight market pressures customer repayments and used-truck pricing, hitting a segment that is easy to overlook inside consolidated results.
• Insider signaling: the CEO's sale of 50,975 shares (~$6.8M) on 2026-07-31 is small in context but landed right after the Q2 beat, and the market noticed.

PACCAR is a genuinely excellent industrial — fortress balance sheet (current ratio 3.12, debt/equity 0.72, cash of $5.57B, positive free cash flow in every quarter but one over three years), a near-record aftermarket parts franchise, $114M/quarter of sustained R&D, and a 2.11% dividend — and the Q2 2026 numbers are the first real evidence that its cyclical trough is behind it (revenue +21% QoQ, operating margin +285bp off the Q4 2025 low, gross margin back to 16.07%). But the stock at $122.73 on 2026-09-13 already trades at 20.6x forward earnings versus a 15.27x five-year average, so the recovery is substantially in the price. This is a hold or an accumulate-on-weakness story, not a buy-at-any-price one: the risk/reward is roughly balanced until either the price pulls back toward the 200-day or Q3 guidance confirms a durable 2027 build cycle.

Mid-cycle earnings-power valuation: I blend 60% weight on next-FY consensus EPS of $5.948 (the recovery year) with 40% weight on a $7.95 normalized mid-cycle EPS (2023-2024 averaged roughly $8.20 diluted, haircut slightly for a structurally smaller North American truck market), giving a blended EPS of $6.75, then apply a 17.5x justified P/E — a premium to the 15.27x five-year average for the aftermarket/parts mix, financial services annuity, and fortress balance sheet, but a discount to the current 20.6x forward multiple to reflect that today's price already discounts a recovery. 17.5 x $6.75 = $118.13, rounded to $118.00, implying the shares are roughly 4% rich as of 2026-09-13.